You just read:

Dauntless Pharmaceuticals Announces Positive Data from Phase 1 Study Investigating Octreotide Formulation for Intranasal Delivery

News provided by

Dauntless Pharmaceuticals, Inc.

May 04, 2017, 10:39 ET